Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of LY3502970 in Healthy Overweight and Obese Participants
NCT05313802Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of orforglipron in obesity (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 42. Started May 2022; status: completed.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05313802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313802.